Michael E. Poole
University of North Carolina at Chapel Hill
6 Papers
58 Citations
Michael E. Poole is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Gemcitabine & Head and neck cancer. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
Phase I Trial of Twice-Weekly Gemcitabine and Concurrent Radiation in Patients With Advanced Pancreatic Cancer
A. William Blackstock,Stephen A. Bernard,Frederick Richards,Kaye S. Eagle,L. Douglas Case,Michael E. Poole,Paul D. Savage,Joel E. Tepper +7 more
TL;DR: A dose of twice-weekly gemcitabine at a 40 mg/m(2) dose produced mild thrombocytopenia, neutropania, nausea, and vomiting when delivered with concurrent radiation to the upper abdomen in patients with advanced pancreatic cancer, suggesting this regimen is well tolerated and may possess significant activity.
250
Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma.
TL;DR: This study indicates that evaluation of adoptive immunotherapy trials in head and neck cancer needs to include parameters other than simple tumor regression as an end point, otherwise therapeutically important lymphokine-induced changes may be missed.
54
•Journal Article
Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.
Stacy S. Shord,Stephen A. Bernard,Celeste Lindley,Andrew Blodgett,Viral Mehta,Mary Ann Churchel,Michael E. Poole,Scott L Pescatore,Feng R. Luo,Stephen G. Chaney +9 more
TL;DR: In this article, the pharmacokinetic parameters of oxaliplatin and Pt(dach)Cl 2 in humans were characterized using high performance liquid chromatography and atomic absorption spectrometry.
37
A phase I study of gemcitabine and docetaxel for advanced stage solid tumors.
Michael E. Poole,Stephen A. Bernard,Mary Ann Churchel,Mark C. Weissler,Benjamin F. Calvo,William G. Cance,David W. Ollila,Mark J. Koruda,Kevin E. Behrns,Frank C. Detterbeck +9 more
TL;DR: In this paper, the maximum tolerated dose of docetaxel in combination with gemcitabine for patients with refractory solid tumors was determined, and the most significant nonhematologic toxicities included fatigue, nausea, vomiting, mucositis, and hypersensitivity reactions.
7
Phase I T rial o f T wice-Weekly G emcitabine a nd C oncurrent Radiation i n P atients W ith A dvanced P ancreatic C ancer
A. William Blackstock,Stephen A. Bernard,Frederick Richards,Kaye S. Eagle,L. Douglas Case,Michael E. Poole,Paul D. Savage,J. E. Tepper +7 more
- 01 Jan 1999
TL;DR: Data suggest this regimen is well tolerated and may possess significant activity, and a dose of twice-weekly gemcitabine at a 40-mg/m2 dose was well tolerated, which produced mild thrombocytopenia, neutropania, nausea, and vomiting when delivered with concurrent radiation to the upper abdomen in patients with advanced pancreatic cancer.